Literature DB >> 9662050

Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay.

H E Naserke1, N Dozio, A G Ziegler, E Bonifacio.   

Abstract

Measurement of insulin autoantibodies (IAA) with a novel micro radiobinding assay which requires only 20 microl of serum was compared with that in a conventional radiobinding assay which uses 600 microl of serum. IAA were measured with both assays in samples from 94 new onset insulin-dependent diabetes mellitus (IDDM) patients, 97 control subjects. and 48 first degree relatives of IDDM patients selected for having IAA in the conventional radiobinding assay. Overall, 227 (95%) of 239 samples tested were concordant. and IAA levels correlated well (r2 = 0.7) between the two assays. Discordant results were obtained in 7 new onset patients, 4 control subjects, and 1 first degree relative, and these had low IAA levels in the respective assays. Sensitivity and specificity in the new onset IDDM patients and control subjects were 69% and 98% for the micro radiobinding assay and 72% and 98% for the conventional radiobinding assay. The use of the micro radiobinding assay should greatly facilitate islet related antibody screening, particularly in children.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662050     DOI: 10.1007/s001250050968

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

1.  Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.

Authors:  M Schlosser; P W Mueller; C Törn; E Bonifacio; P J Bingley
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

2.  Detection of GAD65 autoreactive T-cells by HLA class I tetramers in type 1 diabetic patients.

Authors:  Laura Giuliani; Raffaella Mele; Monica Di Giovine; Laura Altieri; Antonino Crinò; Lucilla Ravà; Alessandra Fierabracci
Journal:  J Biomed Biotechnol       Date:  2009-12-08

3.  'Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes.

Authors:  R M Curnock; C R Reed; S Rokni; J W Broadhurst; P J Bingley; A J K Williams
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

4.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes.

Authors:  L Yu; D T Robles; N Abiru; P Kaur; M Rewers; K Kelemen; G S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

5.  Pregnancy induces nonimmunoglobulin insulin-binding activity in both maternal and cord blood serum.

Authors:  M S Ronkainen; A M Hämäläinen; P Koskela; H K Akerblom; M Knip
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

6.  Autoimmune responses to the beta cell autoantigen, insulin, and the INS VNTR-IDDM2 locus.

Authors:  E Sarugeri; N Dozio; C Belloni; F Meschi; M R Pastore; E Bonifacio
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

7.  A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.

Authors:  D G Alleva; P D Crowe; L Jin; W W Kwok; N Ling; M Gottschalk; P J Conlon; P A Gottlieb; A L Putnam; A Gaur
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

8.  The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes.

Authors:  D Devendra; T S Galloway; S J Horton; A Evenden; U Keller; T J Wilkin
Journal:  Diabetologia       Date:  2003-06-03       Impact factor: 10.122

9.  A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.

Authors:  Bo Zhang; Rajiv B Kumar; Hongjie Dai; Brian J Feldman
Journal:  Nat Med       Date:  2014-07-13       Impact factor: 53.440

Review 10.  Multiple genes/multiple autoantigens role in type 1 diabetes.

Authors:  N Abiru; G S Eisenbarth
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.